Canada Markets open in 6 hrs 25 mins

Medexus Pharmaceuticals Inc. (MDP.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
7.75-0.40 (-4.91%)
At close: 3:54PM EDT
Full screen
Previous Close8.15
Open8.10
Bid7.80 x 0
Ask7.85 x 0
Day's Range7.70 - 8.14
52 Week Range3.27 - 9.75
Volume40,982
Avg. Volume44,528
Market Cap147.959M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-1.81
Earnings DateAug. 09, 2021 - Aug. 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
  • Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada
    GlobeNewswire

    Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada

    TORONTO and CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has received a Notice of Compliance (“NOC”) from Health Canada to commercialize treosulfan, developed by medac GmbH, in Canada, following the satisfactory review of the submission for the bifunctional alkylating agent. Treosulfan will be marketed in Canada under the brand name Trecondyv® and indicated in combination with fludarabine as

  • Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021
    GlobeNewswire

    Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021

    Transformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash equivalents of $18.7 million and available liquidity of $24.8 million at March 31, 2021 Management to host conference call at 8:00 AM Eastern Time on June 17th, 2021 TORONTO and CHICAGO, June 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial and operating results for the fourth quarter and fiscal year e

  • Medexus Announces Graduation to the Toronto Stock Exchange
    GlobeNewswire

    Medexus Announces Graduation to the Toronto Stock Exchange

    TORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) announced today that it has received final approval for listing of the Company’s common shares (the “Common Shares”) on the Toronto Stock Exchange (the “TSX”). In connection with the graduation of the Common Shares, the Company’s convertible debentures (TSXV:MDP.DB, the “Convertible Debentures”) and certain of the Company’s common share purchase